Skip to main content

Advertisement

Table 1 Baseline characteristics of the subjects according to underlying malignancy

From: Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function

  RCC (N = 93) Non-RCC (N = 17)
Male sex , no. (%) 77 (82%) 10 (63%)
Age (years) 59 (52, 67) 54 (48, 59)
BMI (kg/m2) 23.5 (20.0, 25.2) 23.8 (21.4, 25.3)
Diabetes mellitus (%) 17 (18%) 0 (0%)
Hypertension (%) 33 (36%) 2 (11%)
ACE inhibitor/ARB (%) 15 (16%) 1 (6%)
Diuretics (%) 40 (43%) 5 (29%)
Previous TKI Treatment (%) 93 (100%) 9 (53%)
Radical nephrectomy 74 (80%) 0 (0%)
Creatinine (mg/dL) 1.19 (1.01, 1.43) 0.78 (0.64, 0.86)
eGFR (mL/min/1.73 m2) 63 (51, 76) 104 (94, 132)
 >90 10 (11%) 14 (82%)
 60–90 41 (44%) 2 (12%)
 30–60 40 (43%) 1 (6%)
 15–30 2 (2%) 0 (0%)
Proteinuria (%) 25 (28.1%) 0 (0%)
Everolimus   
 Total dose (mg) 1155 (670, 1900) 790 (332, 1825)
 Duration (weeks) 20 (12, 36) 12 (6, 26)
  1. Data are presented as the median (IQR) or number (%).
  2. RCC, renal cell carcinoma; BMI, body mass index; ACE inhibitor, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; TKI, tyrosine kinase inhibitor; eGFR, estimated glomerular filtration rate.